Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug308 | Anti-SARS-CoV-2 equine immunoglobulin fragments (INOSARS) Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
Navigate: Correlations HPO
There is one clinical trial.
Respiratory involvement of SARS-CoV2 leads to acute respiratory distress syndrome (ARDS) and significant immunosuppression (lymphopenia) exposing patients to long ventilation duration and late mortality linked to the acquisition of nosocomial infections. Lymphopenia characteristic of severe forms of ARDS secondary to SARS-CoV2 infection may be linked to expansion of MDSCs and arginine depletion of lymphocytes. Severe forms of COVID-19 pneumonitis are marked by persistent ARDS with acquisition of nosocomial infections as well as by prolonged lymphocytic dysfunction associated with the emergence of MDSC. It has been found in intensive care patients hypoargininaemia, associated with the persistence of organ dysfunction (evaluated by the SOFA score), the occurrence of nosocomial infections and mortality. Also, it has been demonstrated that in these patients, the enteral administration of ARG was not deleterious and increased the synthesis of ornithine, suggesting a preferential use of ARG by the arginase route, without significant increase in argininaemia nor effect on immune functions. L-citrulline (CIT), an endogenous precursor of ARG, is an interesting alternative to increase the availability of ARG. Recent data demonstrate that the administration of CIT in intensive care is not deleterious and that it very significantly reduces mortality in an animal model of sepsis, corrects hypoargininemia, with convincing data on immunological parameters such as lymphopenia, which is associated with mortality, organ dysfunction and the occurrence of nosocomial infections. The availability of ARG directly impacts the mitochondrial metabolism of T lymphocytes and their function. The hypothesis is therefore that CIT supplementation is more effective than the administration of ARG to correct hypoargininaemia, decrease lymphocyte dysfunction, correct immunosuppression and organ dysfunction in septic patients admitted to intensive care. The main objective is to show that, in patients hospitalized in intensive care for ARDS secondary to COVID-19 pneumonia, the group of patients receiving L-citrulline for 7 days, compared to the group receiving placebo, has a score of organ failure decreased on D7 (evaluated by the SOFA score) or by the last known SOFA score if the patient has died or been resuscitated.
Description: SOFA score for organ failures on D7 or last known SOFA score if the patient has died or been resuscitated
Measure: SOFA Time: Day 7Description: Number and phenotype of lymphocytes on days 1, 3, 7, 10 and 14
Measure: Number and phenotype of lymphocytes Time: Days 1, 3, 7, 10 and 14Description: Monocytic expression HLA-DR (Flow cytometry) on days 1, 3, 7, 10 and 14
Measure: HLA-DR Time: Days 1, 3, 7, 10 and 14Description: Number of Myeloid-derived suppressor cells (Flow cytometry) on days 1, 3, 7, 10 and 14
Measure: Number of Myeloid-derived suppressor cells Time: Days 1, 3, 7, 10 and 14Description: Plasma cytokines / chemokines (IL-6, IL-8, IL-10, IL-7, CXCL10, G-CSF, TNF-alpha, IFN-β) at days 1, 3, 7, 10 and 14
Measure: Plasma cytokines / chemokines Time: Days 1, 3, 7, 10 and 14Description: Diversity of the repertoire T at days 1, 3, 7, 10 and 14
Measure: Repertoire T Time: Days 1, 3, 7, 10 and 14Description: T lymphocyte exhaustion: measurement of lymphocyte apoptosis and lymphocyte proliferation on days 1, 3, 7, 10 and 14
Measure: Lymphocyte T exhaustion Time: Days 1, 3, 7, 10 and 14Description: Measurement of mitochondrial activity (measurement of the number of mitochondria and their membrane potential, measurement of the expression of Beclin1) on days 1, 3, 7, 10 and 14
Measure: Mitochondrial activity Time: Days 1, 3, 7, 10 and 14Description: Plasma amino acids (arginine and its metabolites (ornithine, glutamate, glutamine, citrulline, proline) and tryptophan / kynurenine) on days 1, 3, 7, 10 and 14
Measure: Plasma amino acids Time: Days 1, 3, 7, 10 and 14Description: SOFA score of organ failures on days 3, 7, 10 and 14
Measure: SOFA Time: Days 3, 7, 10 and 14Description: Duration of hospitalization in intensive care (days), up to day 28 maximum
Measure: Duration of hospitalization in intensive care Time: Day 28Description: Duration of hospital stay in hospital (days), up to day 28 maximum
Measure: Duration of hospital stay in hospital Time: Day 28Description: Duration of mechanical ventilation (days), up to day 28 maximum
Measure: Duration of mechanical ventilation Time: Day 28Description: Mortality in intensive care on day 28
Measure: Mortality in intensive care on day 28 Time: Day 28Description: Hospital mortality on day 28
Measure: Hospital mortality on day 28 Time: Day 28Description: Measurement of the presence of SARS-CoV2 in the tracheal aspiration by PCR on days 1, 3, 7, 10 and 14
Measure: Measurement of the presence of SARS-CoV2 Time: Days 1, 3, 7, 10 and 14Description: Incidence of nosocomial infections during the intensive care unit (maximum D28). The diagnosis of nosocomial infections will be made according to the definitions of nosocomial infections of the CDC. An independent committee of experts will validate or not the infections
Measure: Nosocomial infections Time: D28Description: Number of days of exposure to each antibiotic per 1000 days of hospitalization (maximum day 28).
Measure: Number of days of exposure to each antibiotic per 1000 days of hospitalization Time: Day 28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports